Dean’s Newsletter
November 15, 2004

Table of Contents
- California Takes a Major Step Forward in Stem Cell Research
- Another Step Toward Our Application to Become an NCI-Designated Comprehensive Cancer Center
- Facilitating Translational Research: The PharmaSTART Initiative
- Update on The Stanford/Packard Center for Translational Medicine (SPCTRM)
- Community Lecture Series on Regenerative Medicine
- Stanford Hosts the California Healthcare Initiative
- Evolving Program in Genomics and Human Genetics
- Meeting on Immersive and Simulation Learning
- Updates from Information Resources and Technology
  - New Research Data management Services from Information Resources and Technology
  - Creation of New Public Web Services Division within Information Resources and Technology
- Annual Celebration to Recognize Our Staff Employees
- DFA Retreat Focuses on Community Service Executive Committee Update: The Office of Communications and Public Affairs
- Katherine D. McCormick Distinguished Lecture
- Awards and Honors
  - Dr. Saul Rosenberg
  - Dr. Karl Deisseroth
  - Dr. Tom Krummel
- Appointments and Promotions

California Takes a Major Step Forward in Stem Cell Research

On Tuesday November 2nd the citizens of California spoke definitively in favor of stem cell research by the passage of Proposition 71. As you probably know, Prop 71 will provide $3 Billion over the next decade to support this important area of research in California. As you also know, stem cell research has been a highly politicized topic during the past 2-3 years and, in no small part because of Stanford contributions in research and advocacy, became a source of debate during the recent presidential election. I guess it would be somewhat revealing of my own personal viewpoint to say that the passage of Prop 71 (as well as 61) was one of the only positive things that occurred on Election Day 2004.

With the passage of Prop 71 comes an enormous responsibility and accountability. It will now be our job to assure that the very best science is performed and that all studies are conducted with the highest ethical standards. It will be incumbent on us to assure that the support and investment by our fellow citizens in California result in fundamental new knowledge about stem cell biology and its relationship to
developmental biology and regenerative medicine. While it is easy to become hyperbolic in suggesting that this research will lead rapidly to new treatment strategies, I do firmly believe that innovations will be developed in the years ahead that will have a major impact on improving the lives of adults and children with serious medical illnesses. These include cancer, diabetes, heart disease, and neurodegenerative disorders, among others. But such progress will take time and can only result from careful and rigorous experimentation.

Our public and private academic institutions and research institutes have the prospect – and, I would add, responsibility – to become the national leaders in stem cell research. While the resources will need to be committed with the highest rigor, they should enable our institutions to develop the infrastructure and facilities to carry out this important work by supporting innovative science and recruiting new talent to contribute to our mission and join our institutions. I hope that we will engage individuals form diverse and different disciplines who will approach these exciting challenges from different perspectives and who will engender new ways of thinking and problem solving. I further hope that the research agenda that evolves will promote new levels of cooperation and collaboration among our various institutions and centers in California. Additionally, I hope that we will collectively further advance and promote the national discussion on this topic, from its basic science and ethics to its implications for therapeutic intervention.

A range of committees and oversight groups will oversee Prop 71. On November 5th, State Controller Steve Westly appointed me to serve on the Independent Citizen’s Oversight Committee. I view this as an important personal responsibility. Some might argue that it will be difficult for individuals to serve on the Oversight Committee when their own institution serves to benefit from funding from Prop 71. I certainly understand and respect that concern. But I also recognize that leadership – whether as the dean of a medical school or a member of a scientific advisory group in the public or private sector – requires putting the rigor and significance of the science before any institutional consideration. Interestingly, even more than other committees or boards on which I have served, the title of “Citizen’s” Oversight Committee addresses a special responsibility. It will be incumbent on each member of this committee – or the science review boards – to approach this responsibility as a citizen first. In this case that means assuring to the very best of our ability that the commitment and investment that our fellow citizens have made by the passage of Prop 71 results in the highest quality outcomes. Certainly that is how I will approach this important responsibility.

**Another Step Toward Our Application to Become an NCI-Designated Comprehensive Cancer Center**

I have discussed in prior Dean’s Newsletter our plans to become an NCI-Designated Comprehensive Cancer Center. Over the past 18 months we have made considerable strides in advancing our planning efforts, due largely to the untiring efforts of Dr. Karl Blume, Professor of Medicine, Emeritus, and Associate Director of the Cancer /Stem Cell Institute. During this period we have defined the eight major programs
and share resources (or cores) that will comprise our grant application (see below). We have also formed an important collaboration with the Northern California Cancer Center (NCCC) that will enhance our efforts in cancer epidemiology and population research. This collaboration has been enriched by the appointment of Dr. Dee West, of the NCCC, as Professor of Health Research and Policy at Stanford. In tandem, we are also expanding our faculty in cancer biostatistics with the appointment of Dr. Phil Lavori, Professor of Health Research and Policy, as the leader of this program along with the planned recruitment of additional faculty in clinical epidemiology and biostatistics. Of course our greatest strength lies in innovation and technology development – a fact that was certainly well appreciated by the review from our External Advisory Board this past March.

One of the other major critical components of our planned proposal to the NCI has been identifying the Principal Investigator (PI) for the grant application. During the past year the Steering Committee of our Cancer/Stem Cell Institute reviewed a series of candidates, focusing on individuals who are outstanding scientists. While our initial hope had been to recruit an external leader, I have decided that we will make greater progress with an internal scientist and I have asked Irv Weissman, the Director of the Cancer/Stem Cell Institute, to serve as the initial PI. I am very pleased to announce that Dr. Weissman has agreed to do so. Dr. Weissman brings enormous distinction and credibility as a scientist and leader. Our current plan is to complement Dr. Weissman’s leadership through the appointment of a strong Deputy Director, and a search for this individual is now underway.

Accordingly, the current plans for our NCI application has an array of projects, including:

1. **Basic Science Programs**

<table>
<thead>
<tr>
<th>Project</th>
<th>Principal and Co-Investigators</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cancer/Stem Cell Biology</td>
<td>I. Weissman, R. Nusse</td>
</tr>
<tr>
<td>Radiation Biology</td>
<td>A. Giaccia, Q. Le</td>
</tr>
<tr>
<td>Cancer Biology</td>
<td>M. Cleary, L. Boxer</td>
</tr>
<tr>
<td>Cancer Imaging</td>
<td>S. Gambir, C. Contag</td>
</tr>
</tbody>
</table>

2. **Clinical Science Programs**

<table>
<thead>
<tr>
<th>Project</th>
<th>Principal and Co-Investigators</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systematic Molecular Profiling of Cancer</td>
<td>P. Brown, S. Jeffrey</td>
</tr>
<tr>
<td>Lymphoma and Hodgkin Disease</td>
<td>R. Levy, S. Horning</td>
</tr>
<tr>
<td>Immunology and Immunotherapy of Cancer</td>
<td>E. Engleman, M Davis</td>
</tr>
<tr>
<td>Adult and Pediatric Hematopoietic Cell Transplantation</td>
<td>R. Negrin</td>
</tr>
</tbody>
</table>

3. **Population Science Programs**

<table>
<thead>
<tr>
<th>Project</th>
<th>Principal and Co-Investigators</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cancer Epidemiology/Cancer</td>
<td>D. West, A. Whittemore</td>
</tr>
</tbody>
</table>
Prevention/Outcomes Research/Patient Education

In addition, the following group of Cores will be a critically important part of the grant application:

<table>
<thead>
<tr>
<th><strong>Shared Resources (Cores)</strong></th>
<th><strong>Principal and Co-Investigators</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Biostatistics Core for Cancer Research</td>
<td>P. Lavori, B. Brown, T. Lai</td>
</tr>
<tr>
<td>Clinical Trials Support Office</td>
<td>G. Fisher</td>
</tr>
<tr>
<td>Informatics Core</td>
<td>H. Lowe</td>
</tr>
<tr>
<td>General and Specialized Animal Colonies</td>
<td>R. Tolwani, M. Garcia</td>
</tr>
<tr>
<td>Transgenic and Knockout Mice</td>
<td>M. Cleary, D. Felscher, Y. Chen Tsai</td>
</tr>
<tr>
<td>Cell and Tissue Distribution</td>
<td>J. Pollack, J. Norton</td>
</tr>
<tr>
<td>Cancer Imaging</td>
<td>C. Contag, S. Gambir, B. Daniel</td>
</tr>
<tr>
<td>Confocal and Immunoelectron Microscopy</td>
<td>S. Smith, J. Mulholland</td>
</tr>
<tr>
<td>Flow Cytometry</td>
<td>G. Nolan, L. Herzenberg</td>
</tr>
<tr>
<td>DNA Microarrays</td>
<td>G. Sherlock, M. Fero, C. Ball</td>
</tr>
<tr>
<td>High throughput Genomic Analyses</td>
<td>R. Davis, M. Mindrinos, W. Xiao, H. Ji</td>
</tr>
</tbody>
</table>

And there are some developing programs as well. These include:

<table>
<thead>
<tr>
<th><strong>Developing Programs</strong></th>
<th><strong>Program Leaders</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Biomedical Informatics and Biomedical Computation</td>
<td>M. Musen, S. Plevritis</td>
</tr>
<tr>
<td>Pediatric Cancer Research</td>
<td>M. Link, G. Dahl</td>
</tr>
<tr>
<td>Cancer Pharmacology and Experimental Therapeutics</td>
<td>B. Sikic, K. Cimprich</td>
</tr>
<tr>
<td>Genetics of Solid Tumors</td>
<td>J. Ford, R. Davis</td>
</tr>
</tbody>
</table>

While the proposal will contain an broad array of activities, it will also have an additional, unique component arising from Dr. Weissman’s quest for cancer stem cells and for the ultimate development of disease specific cancer stem cell lines generated by nuclear transfer experiments. The initiation of these studies will engage faculty from a number of departments and will also include the recruitment of new faculty members. Because laboratory space is so very limited at this moment, the locus of the activity will likely take place at 1050 Arastradero, which we are now referring to as the “vineyard” (since it truly has one in its front yard) until our Stanford Institutes of Medicine building is constructed, hopefully within the next 3-4 years.

I also recently had the opportunity, during a recent trip to New York City, to review our developing plans in this area with the executive and scientific directors of the Ludwig Institute. They were quite excited by our overall plans for cancer research, our unique focus on cancer/stem cell biology, and my decision to appointment Dr. Weissman as our PI.
Our association with the Ludwig Institute as well as the NCI will help shape our future programs in cancer research. While we have considerable work to do, I am pleased with our progress to date and enthusiastic about the immediate challenges and opportunities that stand before us.

**Facilitating Translational Research: The PharmaSTART Initiative**

I have previously described the formation of PharmaSTART as a unique collaboration between Stanford, UCSD, UCSF, UC-Berkeley and Stanford Research Institute (SRI) to foster and develop early development of targeted therapies (see January 24th Dean’s Newsletter. On November 1st, Dr. Ted Spack, Senior Director of the PharmaSTART Program, gave a presentation at Stanford on “Grant Teaming Opportunities in Translational Research and Development”

Over the past several years funding from biotech has shifted to later stages of drug development. This change has resulted in decreased funding for start-ups (with fewer spinouts from single discovery/technology); decreased licensing of academic projects and chaperoning by venture capitalists; and greater potential gaps in the product pipeline. Various institutions have sought to address this challenge in different ways, including a consortium model like PharmaSTART. In this model, SRI - provides its preclinical expertise for the development of targeted chemical or biological agents, focusing particularly on formulation, toxicity, pharmacokinetics and adverse drug interactions. These are all important components or prerequisites to Phase I/II clinical trials. The advantage of the consortium is that it brings together several leading institutions that can collaborate and form the nexus for a regional translational network.

If you wish to learn more about PharmaSTART feel free to contact Dr. Harry Greenberg, Senior Associate Dean for Research (Harry.Greenberg@stanford.edu) or, at SRI, Dr. Ted Spack, PharmaSTART Director (ted.spack@sri.com), Bob Dehn, Director of Government Grant Teaming (bob.dehn@sri.com), or Jim McNamara, Director of Business Development (jim.mcnamara@sri.com).

**Update on The Stanford/Packard Center for Translational Medicine (SPCTRM)**

For almost two years, representatives of the leadership of SUMC as well as the University, in recognition of the need for an improved infrastructure and support system for clinical and translational research, have been engaged in a collaborative effort to re-engineer the entire clinical research enterprise. One of their major thrusts has been the development of the Stanford/Packard Center for Translational Medicine (SPCTRM). SPCTRM, which will be officially launched within the next several months, will be a multi-disciplinary service organization with the goal of enhancing the quality of clinical and translational research performed at Stanford. It will provide comprehensive collaborative support, education, training, and research infrastructure development for members of the Stanford clinical research community. SPCTRM will be a program of
integrated services designed to assist the clinical investigator every step of the way from protocol design and development, to study completion and close out, to data analysis.

In addition, SPCTRM will assume the research coordinator education, training and monitoring functions previously performed by the School’s clinical trials office, ACCESS (Academic Consortium for Clinical Excellence in Scientific Studies). It is also developing new educational programs directed toward investigators and trainees. SPCTRM will provide the following services:

- Assistance with protocol development via biostatistics and informatics consultation services.
- Study budgeting.
- Contracting.
- Automated billing, accounting, and internal financial auditing.
- Sponsor billing and study closeout.
- Internal compliance monitoring.
- Outpatient clinic space.
- Clinical laboratory consultation and samples processing.
- Study source document archiving.
- Research coordinator services: education, orientation and training; health screening; competency testing.
- Faculty investigator education and training.
- Assistance with external audits and reviews.
- Ombudsman and single point of contact for clinical research issues.
- Stanford Clinical Trials Website

Two dedicated groups have been working on these issues. The Stanford/Packard Task Force on Translational Medicine consists of: Steve Alexander, Harry Greenberg, Nick Gaich, Connie Hartnett, Carole Klove, David Haray, Gary May, Ann James, Pamela Webb, Dale Jung, Susie Lu, Steve Jun, Jim Zehnder, Debra Mattman, Miriam Bischoff, Todd Ferris, Nancy Lee, Renee Ritlet, and Brandy Sikic. The SPCTRM ad hoc Working Group includes: Steve Alexander, Harry Greenberg, Alexa Kimball, Mark Genovese, Chris Zarins, Lorrin Koran, Branimer Sikic, Ken Cox, Norm Rizk, Rick Kraemer, Bill Brown, Bill Mobley, Henry Lowe, and Phil Lavori. Many thanks to all for their efforts.

I will keep you informed about the further developments of SPCTRM. I am gratified to see the progress that has been made to date, and I look forward to seeing the implementation of its programs in the near future.

Community Lecture Series on Regenerative Medicine

On Wednesday November 3rd, a wonderful presentation in our Medicine for the Community Lecture series was given on the Promise of Regenerative Medicine – a most timely event in light of the passage of Proposition 71. Special thanks go to Professors Minx Fuller, Seung Kim and Michael Longaker for an enormously informative evening
that addressed the spectrum from basic developmental biology to stem cell biology and applications in regenerative medicine. These evening sessions continue to be well attended by diverse and receptive audiences.

The next session in this series will be “Skin Cancer” on February 2, 2005 presented by Drs. Hayes Gladstone, Youn H. Kim, Anthony Oro, and Susan Swetter.

**Stanford Hosts the California Healthcare Initiative**

On November 9th the Stanford University School of Medicine hosted the California Healthcare Institute’s (CHI) 2004 Policy Forum. The meeting brought together federal and state policy makers with leading biomedical researchers and biotech industry leaders to discuss public policy issues related to bringing breakthrough treatments from the lab to those suffering from disease. We were also very happy to host Congresswoman Anna Eshoo, one of the forums’ keynote speakers and our hometown representative, who has done so much to support biomedical research from her post on the House Energy and Commerce Committee. The Stanford community was well represented during the event, including presentations by Dr. Paul Berg, the Robert W. and Vivian K. Cahill Professor of Cancer Research Emeritus, on the future of stem cell research in California after the passage of Proposition 71 and Dr. Alan Garber, the Henry J. Kaiser Jr. Professor of Health Research and Policy, on the public policy issues related to assessing the economic value of biomedical innovation. This was the second CHI event we have hosted at Stanford and we look forward to continued dialogue on these important issues.

**Evolving Program in Genomics and Human Genetics**

As I discussed in the October 4th Dean’s Newsletter, we are in the process of forming three Strategic Centers that will form a matrix with our Stanford Institutes of Medicine. They will further enhance the linkage between basic science and clinical medicine and, in so doing, will foster Translating Discoveries (see Strategic Plan [http://medstrategicplan.stanford.edu/](http://medstrategicplan.stanford.edu/)). The three Strategic Centers (this descriptor may well change) include Genomics and Human Genetics (led by Dr. Rick Myers, Stanford W. Ascherman M.D., F.A.C.S. Professor of Genetics), Clinical Informatics (led by Dr. Henry Lowe, Senior Associate Dean for Information Resources and Technology) and Clinical Imaging (led by Drs. Gary Glazer, Emma Pfeiffer Merner Professor in the Medical Sciences, and Sam Gambir, Professor of Radiology).

Planning for the Genomics and Human Genetics and the Clinical Informatics Enabling Centers is well underway. On Saturday, October 30th, a Genomics and Human Genetics Retreat was attended by more than 50 faculty, with many more expressing an interest in this new effort. It focused on a broad scientific agenda and especially on various experimental model systems for genomic approaches and how these inform human genomic research. As an outcome of the retreat a weekly series of faculty meetings will be launched in December as a forum for further shaping the agenda and focus of this Center.
A number of initiatives are already being planned, including training grant proposals, developing means for faster dissemination of exciting new technologies developed within Stanford, exploration of ways to better link our two major genome centers, mechanisms for enabling model organisms to “feed off” of one another, better access to existing clinical samples, clearer definition of how proteomics will contribute to the genomics initiative, improved infrastructure support for genetic epidemiology, overall facilities and program support for important initiatives, and greater physician involvement. This of course is just a start since this exciting initiative will be further shaped over the next weeks and months. Faculty who have an interest in this new effort should contact Rick Myers (Myers@SHGC.stanford.edu).

Meeting on Immersive and Simulation Learning

An exciting program of events is occurring on Monday, November 15, 2004 to launch the School of Medicine's new initiative on immersive and simulation-based learning (ISL). Session I features distinguished guest speakers, including outside experts on immersive and simulation-based learning in both surgical and a variety of dynamic non-surgical fields. In addition, leaders of Stanford's four founding centers of simulation activity are giving highlights and demonstrations of their work. Speakers for the morning event include:

- **Henry Lowe, M.D.**, Senior Associate Dean for Information, Resources, and Technology
- **David Gaba, M.D.**, the newly appointed Associate Dean for Immersive and Simulation-based Learning at Stanford School of Medicine. This new office will develop programs to encourage Stanford faculty to create, deploy, and integrate applications of ISL for education, training, research, and improvement of clinical care. Strategic planning is currently underway toward the intended establishment of a Center for Immersive and Simulation Based Learning.
- **Ajit Sachdeva, M.D.** Director, Division of Education, American College of Surgeons. The ACS is actively engaged in delineating mechanisms to bring simulation-based training to its members and to residents in training.
- **Amitai Ziv, M.D.**, Director, Israel National Simulation Center, Chaim Sheba Medical Center. This national simulation center is involved with a large number of applications in a diverse set of medical fields. The unique needs and small size of this country promote innovative national solutions to critical requirements of training and assessment.
- **Lou Halamek, M.D.**, representing the Center for Advanced Pediatric Education (CAPE)
- **Thomas Krummel, M.D.**, representing the Center for Simulation in Medicine (CSIM),
- **Parvati Dev, Ph.D.**, representing Stanford University Medical Media and Instructional Technology (SUMMIT),
- **Steve Howard, M.D.**, representing the Patient Simulation Center of Innovation at VA Palo Alto Health Care System (PSCI).
Session II is a gathering for Stanford faculty and invited guests to discuss the opportunities, structures, and resources for the implementation of ISL across the entire school and affiliated hospitals. The session also addresses where and how ISL might fill gaps in the education and training of clinicians ranging from students to experienced practitioners. The program information can be found at http://med.stanford.edu/irt/immersive/. This is an exciting new undertaking for the Stanford University Medical Center, and I am confident that it will elicit broad interest both within the School and externally.

Updates from Information Resources and Technology

Dr. Henry Lowe, Senior Associate Dean for IRT asked me to share the following two announcements with you:

New Research Data management Services from Information Resources and Technology

The IRT System Development division, under the direction of Phil Constantinou, is being renamed Systems Development and Data Management to reflect that division's new role of providing research data management services to the SUMC community. These new services will include consultation on research data management options, design and implementation of research databases, design and development of research applications and, in close collaboration with IRT's IT Services and Security & Privacy groups, ongoing operation of research data management systems. These new services will be deployed incrementally in close collaboration with the Stanford research and biostatistics community. Dr. Lowe and I am very grateful to Phil Constantinou, and his team, for taking on this important responsibility and have great confidence that they will provide excellent services supporting the School's research mission. For full information about Systems Development and Data Management please see http://med.stanford.edu/irt/development/

Creation of New Public Web Services Division within Information Resources and Technology

Dr. Lowe and I are pleased to announce the promotion of Michael Halaas to Director of Public Web Services within IRT. This new division, under Michael's leadership, provides general oversight for the School of Medicine's web presence and a wide range of support for the more than 300 public websites associated with the school. Public Web Services sets web publishing standards and policies, provides training and support for departmental web authors, and builds websites for groups across the school. Earlier this year, the group began a major renovation of the school's website and is in the midst of rebuilding sites for all departments, centers, and institutes into a common and flexible design framework with the goal of providing strong coordination of the various public facing web-related activities. The group also builds and manages web applications associated with the public web including CAP (Community
Academic Profiles), a system for publishing and managing profiles for our faculty and researchers. For full information about the Public Web Services division please see http://med.stanford.edu/irt/web/

**Annual Celebration to Recognize Our Staff Employees**

One of the most wonderful events each year is the Dean’s Staff Recognition Dinner. This event allows us to thank School of Medicine staff who have served for 5, 10, 15, 20, 25, 30, 35, 40 and (even) 45 years of service. I want to begin by thanking our Human Resource Department, led by Ms Cori Bossenberry, and Michael Hindery, our Senior Associate Dean for Finance and Administration, for making this event so successful. As I meet the individuals who are being honored at this event, I am comforted by how dedicated and committed they are to Stanford. There is no doubt that many have experienced all the stresses and strains that go along with working in the intense environment that defines a modern academic medical center. But an individual and collective commitment, wisdom and dedication were abundantly visible at this annual celebration and are what helps to make our Medical School so truly excellent. Whether serving as administrators, research technologists, animal caretakers, communicators, fundraisers, or in any of the many other roles in the School, each employee brings a unique and special perspective and personal set of talents. I want to thank each one for his or her many contributions.

Having myself been part of the Stanford community for less than four years, it is gratifying (and humbling) to note how many individuals have served Stanford for two, three and four or more decades. These individuals are listed below and include:

**20 YEAR EMPLOYEES**

- **Stuart Anhorn**  
  Comparative Medicine/Vet Service Ctr
- **Rose Sage Barone**  
  SOM/IRT Operations
- **Gail Benson**  
  Anesthesia
- **Francena Brumbaugh**  
  Medicine/General Internal Medicine
- **Jim Day**  
  SOM/Visual Art Services
- **Maria Bernardette De Souza**  
  Pathology/Blood Center
- **Sharon Dickow**  
  Medicine/Immunology & Rheumatology
- **Emily Gere**  
  Psychiatry
- **Kathryn Gillam**  
  SOM/Dean's Office Operations
- **Charlene Hamada**  
  SOM/Student Affairs
- **Katherine Ishizuka**  
  Pathology
- **Vivian Jones**  
  SOM/Facilities Planning & Mgmt
- **Sharie Kumaishi**  
  SOM/IRT Operations
- **Christelle Lukrich**  
  SOM/Human Resources Group
- **Sally Mackey**  
  Medicine/SPRC
- **Dennis Mitchell**  
  Microbiology & Immunology/Baxter Labs
- **Christa Parrish**  
  Pediatrics
- **Elizabeth Peairs**  
  SOM/Grad Student Support
Bruce Seidel  
Jacqueline Signor  
Susan Singh  
Maurice Tan  
Martha Trujillo  
Thanh Vu  
Alayne West  
Mo-Oi Chang Yee  

SOM/IRT Operations  
ObGyn  
Radiology  
Pathology/Blood Center  
SOM/Student Affairs  
Medicine/Endocrinology  
Genetics  
SOM/General Clinical Rsch Cntr

25 YEAR EMPLOYEES  
Bethany Ball  
Catharine Booth  
Katherine Dochez  
Kathleen Dugan  
Michelle Ferrari  
Julian Hinojoza  
Gina Jager  
Jean Jang  
Susan Johnson  
Robyn Kizer  
Phyllis Knudsen  
Anna Korossy-Eredia  
Linda Lew  
Jeannie Lukas  
Elizabeth McCormick  
Carmencita Nicolas  
Sharon Seliga  
Richard Smith  

Pediatrics  
Molecular and Cellular Physiology  
Medical Development  
Medicine/Hematology  
Urology  
Pathology  
Microbiology & Immunology/Baxter Labs  
Pathology  
Medicine/Nephrology  
Medicine/Immunology & Rheumatology  
Neurobiology  
Medicine/Gastroenterology & Hepatology  
Pediatrics  
Structural Biology  
Medicine/Oncology  
Pathology  
SOM/IRT Operations  
SOM/Research Mgmt Group

30 YEAR EMPLOYEES  
Marcia Bieber  
Beverly Bonfert  
Yvonne Cheng  
Mary Jane Eaton  
Pamela Petrie  
Robert Marshall  
Maureen Rittenberg  
Gerald Weitz  

ObGyn  
Cardiothoracic Surgery  
Biochemistry  
Pathology  
SOM/IRT Operations  
Neurobiology  
SOM/SA Dean of Research Oper  
SOM/IRT Operations

35 YEAR EMPLOYEE  
Tom Nozaki  
Lilia Gabisan  

Genetics  
Medicine/Oncology
DFA Retreat Focuses on Community Service

During the last week of October, Mike Hindery, Senior Associate Dean for Finance and Administration brought together the Departments’ Directors of Finance and Administration and senior managers in the Dean’s Office for their seventh annual retreat. However, instead of doing strategic planning or staff development, or listening to a motivational speaker, they banded together to perform community service for three local organizations. The 2004 annual retreat was designated as “Team-Building through Community Service” and included partial day sessions with the Haven Family House, the Ronald McDonald House and the Second Harvest Food Bank.

- At Haven Family House, which provides temporary family housing and day care services to families who need help getting back on their feet, the group worked on raised vegetable beds that formed a beautiful garden and will help feed the families housed there.

- At Ronald McDonald House, which provides “home-away-from-home” facilities for families with children receiving care at LPCH, they put up Halloween decorations for the children.

- At Second Harvest Food Bank they processed 1000 donation cans that will enable the organization to collect money to fund their provision of meals to low-income children, adults and seniors.

Each of these organizations provides valuable services to the community and the School is thrilled to be associated with them. This “retreat” gave our senior managers and organization an opportunity to help others and give back to the community that we are serving and do some team building along the way. I’m told that the group accomplished a great deal but also thoroughly enjoyed themselves.

Update From the Executive Committee: The School of Medicine Office of Communications and Public Affairs

At the November 5th Executive Committee meeting, Paul Costello, Executive Director of the Office of Communications and Public Affairs, provided an overview of the work of his group. The Office covers print and web communications as well as media relations. In the area of print and web communications, the Office publishes 38
issues annually of the Medical Center Report, which is an insert of the weekly Stanford Report newspaper. The beat reporters/writers cover research and medical breakthroughs. In addition, the Office publishes the magazine Stanford Medicine three times a year. They also post content on the School of Medicine home page and throughout the web site. The Communications and Public Affairs web site received 39,000 hits in August and 49,550 in September.

In the area of media relations, the Office pitches stories to the media, handles press inquiries, advises faculty on handling the press, and focuses on two areas: print and broadcast. During the past nine months, the Office has issued 85 press releases of studies, research, and personnel announcements, handled 1,100 print media calls, 500 broadcast media inquiries, and has had 2,600 media hits. It has also conducted three media training sessions and has two more scheduled. Paul explained that the strategic goals of the Office of Communications and Public Affairs are: to support the mission of the School of Medicine, to support the fund-raising goals of the School of Medicine, to promote the scientific and medical innovations that occur in the School, and to promote thought leadership on the part of members of the Stanford community.

I would only add that I am, of course, very pleased that our Office of Communications and Public Affairs is both highly responsive and strategically proactive. It is well aligned with the goals of the School and is making major contributions to our progress in many areas. Thanks to Paul and all of the members of his staff for their many efforts.

Katherine D. McCormick Distinguished Lecture

The Faculty Selection Committee for the Katherine D. McCormick Distinguished Lecture Series, has informed me that this year's McCormick Lecture will be given by Dr. Huda Zoghbi, Howard Hughes Investigator and Professor in the Departments of Pediatrics, Neuroscience and Molecular and Human Genetics at Baylor College of Medicine. Dr. Zoghbi will speak on Tuesday, November 30 at 4:30 pm, on "Breaking Down the Pathogenesis of a Neurodegenerative Disease Using Cross-Species Studies" in Fairchild Auditorium. The lecture is free and open to the public, and a reception with refreshments will follow the lecture.

The members of the Katherine D. McCormick Distinguished Lecture Selection Committee are: Erick Knudson, Professor of Neurobiology, Alfred Lane, Professor of Dermatology, Robert Malenka, Professor of Psychiatry and Behavioral Sciences, Marlene Rabinovich, Professor of Pediatrics, Lucy Shapiro, Professor of Developmental Biology, and Judy Swain, Chair and Professor, Department of Medicine.

Awards and Honors

• Dr. Saul Rosenberg Maureen Lyles D'Ambrogio Professor in the School of Medicine, Emeritus received the first Rosetta Medical Award of the Lymphoma Research Foundation. The presentation was made at a gala event in San Francisco on October 28.
• **Karl Deisseroth**, Assistant Professor of Bioengineering and Psychiatry, has been named one of three academic physicians in the United States to receive a prestigious Charles E. Culpeper Scholarship in Medical Science, a program designed to support the career development of academic physicians. Congratulations to Karl!

• **Dr. Tom Krummel**, Emile Holman Professor and Chair of the Department of Surgery at SUMC and Susan B. Ford Surgeon-in-Chief at LPCH, has been elected a Director of the prestigious James IV Association of Surgeons. Congratulations to Dr. Krummel.

## Appointments and Promotions

- **Paul Buckmaster** has been promoted to Associate Professor of Comparative Medicine and of Neurology and Neurological Sciences, effective 11/1/2004.
- **Linda Boxer** has been promoted to Professor of Medicine (Hematology), effective 11/1/2004.
- **Steven Coutre** has been promoted to Associate Professor of Medicine (Hematology) at the Stanford University Medical Center, effective 11/1/2004.
- **Steven Foung** has been promoted to Professor of Pathology, effective 12/1/2004.
- **Ware Kuschner** has been promoted to Associate Professor of Medicine (Pulmonary and Critical Care Medicine) at the Veterans Affairs, Palo Alto Health Care System, effective 11/1/2004.
- **Ann Leung** has been promoted to Professor of Radiology at the Stanford University Medical Center, effective 11/1/2004.
- **James Quinn** has been appointed to Associate Professor of Surgery (Emergency Medicine) at the Stanford University Medical Center, effective 11/1/2004.
- **Randall Stafford** has been promoted to Associate Professor of Medicine, effective 12/1/2004.
- **Susan Swetter** has been promoted to Associate Professor of Dermatology at the Veterans Affairs Palo Alto Health Care System, effective 11/1/2004.